KR102491308B1 - Cyp11a1 (시토크롬 p450 모노옥시게나제 11a1) 억제제로서 피란 유도체 - Google Patents

Cyp11a1 (시토크롬 p450 모노옥시게나제 11a1) 억제제로서 피란 유도체 Download PDF

Info

Publication number
KR102491308B1
KR102491308B1 KR1020197021256A KR20197021256A KR102491308B1 KR 102491308 B1 KR102491308 B1 KR 102491308B1 KR 1020197021256 A KR1020197021256 A KR 1020197021256A KR 20197021256 A KR20197021256 A KR 20197021256A KR 102491308 B1 KR102491308 B1 KR 102491308B1
Authority
KR
South Korea
Prior art keywords
alkyl
pyran
compound
methyl
isoindolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197021256A
Other languages
English (en)
Korean (ko)
Other versions
KR20190095950A (ko
Inventor
벨레 다비드 딘
미코 매켈래
미코 파시니에미
페카 피에티캐이넨
페테리 루마코
에이자 티아이넨
마티 바이스마
게르드 보흘파흐르트
Original Assignee
오리온 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오리온 코포레이션 filed Critical 오리온 코포레이션
Priority to KR1020237002074A priority Critical patent/KR102826021B1/ko
Publication of KR20190095950A publication Critical patent/KR20190095950A/ko
Application granted granted Critical
Publication of KR102491308B1 publication Critical patent/KR102491308B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
KR1020197021256A 2016-12-22 2017-12-21 Cyp11a1 (시토크롬 p450 모노옥시게나제 11a1) 억제제로서 피란 유도체 Active KR102491308B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237002074A KR102826021B1 (ko) 2016-12-22 2017-12-21 Cyp11a1 (시토크롬 p450 모노옥시게나제 11a1) 억제제로서 피란 유도체

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20166024 2016-12-22
FI20166024 2016-12-22
PCT/FI2017/050926 WO2018115591A1 (en) 2016-12-22 2017-12-21 Pyran dervatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237002074A Division KR102826021B1 (ko) 2016-12-22 2017-12-21 Cyp11a1 (시토크롬 p450 모노옥시게나제 11a1) 억제제로서 피란 유도체

Publications (2)

Publication Number Publication Date
KR20190095950A KR20190095950A (ko) 2019-08-16
KR102491308B1 true KR102491308B1 (ko) 2023-01-27

Family

ID=61005837

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020257020993A Pending KR20250097993A (ko) 2016-12-22 2017-12-21 Cyp11a1 (시토크롬 p450 모노옥시게나제 11a1) 억제제로서 피란 유도체
KR1020237002074A Active KR102826021B1 (ko) 2016-12-22 2017-12-21 Cyp11a1 (시토크롬 p450 모노옥시게나제 11a1) 억제제로서 피란 유도체
KR1020197021256A Active KR102491308B1 (ko) 2016-12-22 2017-12-21 Cyp11a1 (시토크롬 p450 모노옥시게나제 11a1) 억제제로서 피란 유도체

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020257020993A Pending KR20250097993A (ko) 2016-12-22 2017-12-21 Cyp11a1 (시토크롬 p450 모노옥시게나제 11a1) 억제제로서 피란 유도체
KR1020237002074A Active KR102826021B1 (ko) 2016-12-22 2017-12-21 Cyp11a1 (시토크롬 p450 모노옥시게나제 11a1) 억제제로서 피란 유도체

Country Status (31)

Country Link
US (4) US10717726B2 (enExample)
EP (2) EP3868756A1 (enExample)
JP (2) JP7025432B2 (enExample)
KR (3) KR20250097993A (enExample)
CN (2) CN116162084B (enExample)
AR (1) AR110412A1 (enExample)
AU (2) AU2017380282B2 (enExample)
CA (1) CA3047370A1 (enExample)
CL (1) CL2019001728A1 (enExample)
CO (1) CO2019007321A2 (enExample)
CY (1) CY1124461T1 (enExample)
DK (1) DK3558981T3 (enExample)
EA (1) EA039309B1 (enExample)
ES (1) ES2880151T3 (enExample)
HR (1) HRP20211255T1 (enExample)
HU (1) HUE056540T2 (enExample)
IL (2) IL267484B (enExample)
LT (1) LT3558981T (enExample)
MA (2) MA47102B1 (enExample)
MX (1) MX388538B (enExample)
NZ (1) NZ755395A (enExample)
PE (1) PE20191137A1 (enExample)
PH (1) PH12019550111A1 (enExample)
PL (1) PL3558981T3 (enExample)
PT (1) PT3558981T (enExample)
RS (1) RS62198B1 (enExample)
SI (1) SI3558981T1 (enExample)
TN (1) TN2019000189A1 (enExample)
TW (2) TWI796205B (enExample)
UA (1) UA124640C2 (enExample)
WO (1) WO2018115591A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230019496A (ko) * 2016-12-22 2023-02-08 오리온 코포레이션 Cyp11a1 (시토크롬 p450 모노옥시게나제 11a1) 억제제로서 피란 유도체

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115551831A (zh) 2020-05-14 2022-12-30 奥赖恩公司 Cyp11a1抑制剂
WO2022117920A1 (en) 2020-12-01 2022-06-09 Orion Corporation 2,3-dihydro-4h-benzo[b][1,4]oxazin-4-yl)(5-(phenyl)-pyridin-3-yl)methanone derivatives and similar compounds as cyp11a1 inhibitors for the treatment of prostate cancer
AU2022228710A1 (en) * 2021-03-01 2023-09-07 Orion Corporation Process for the preparation of a cyp11a1 inhibitor and intermediates thereof
US20240158378A1 (en) 2021-03-01 2024-05-16 Orion Corporation Solid forms of a 4h-pyran-4-one structured cyp11a1 inhibitor
AR124985A1 (es) 2021-03-01 2023-05-24 Orion Corp Nuevas formas de sal de un inhibidor de cyp11a1 estructurado en 4h-piran-4-ona
US20240336603A1 (en) 2021-06-23 2024-10-10 Orion Corporation Process for the preparation of a cyp11a1 inhibitor and intermediates thereof
CA3232600A1 (en) * 2021-09-28 2023-04-06 Tarja IKONEN Cyp11a1 inhibitor for use in the treatment of prostate cancer
WO2023073285A1 (en) 2021-10-28 2023-05-04 Orion Corporation Salt forms of a 4h-pyran-4-one structured cyp11 at inhibitor
US20250011285A1 (en) 2021-11-10 2025-01-09 Orion Corporation Cyp11a1 inhibitors
JP2025502308A (ja) 2022-01-20 2025-01-24 オリオン・コーポレーション Ｃｙｐ１１ａ１阻害剤の医薬組成物
CN118307519A (zh) 2023-01-06 2024-07-09 上海闻耐医药科技有限公司 一类cyp11a1抑制剂化合物及其制备方法和用途
KR20240126916A (ko) 2023-02-14 2024-08-22 경북대학교 산학협력단 Asm 단백질 또는 이의 단편을 포함하는 퇴행성 신경질환 또는 우울증 예방 또는 치료용 조성물
KR20250161566A (ko) 2023-03-29 2025-11-17 시젱 하이스코 파마수티칼 씨오., 엘티디. Cyp11a1 억제제 및 이의 용도
WO2024217531A1 (zh) * 2023-04-21 2024-10-24 西藏海思科制药有限公司 Cyp11a1抑制剂及其用途
AU2024270498A1 (en) * 2023-05-11 2025-11-27 Foshan Ionova Biotherapeutics Co., Inc. Novel compounds as cyp11a1 inhibitors and methods of use thereof
WO2025017072A1 (en) 2023-07-19 2025-01-23 Orion Corporation Stable pharmaceutical compositions of a cyp11a1 inhibitor
WO2025021182A1 (en) * 2023-07-27 2025-01-30 Acerand Therapeutics (Hong Kong) Limited Cyp11a1 inhibitors
WO2025051216A1 (zh) * 2023-09-08 2025-03-13 深圳众格生物科技有限公司 一种cyp11a1抑制剂、其制备方法及其应用
WO2025168117A1 (zh) * 2024-02-08 2025-08-14 盛睿泽华医药科技（苏州）有限公司 一种多环化合物及其制备方法和应用
WO2025237211A1 (zh) * 2024-05-11 2025-11-20 辽宁海思科制药有限公司 一种cyp11a1抑制剂的晶型物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076445A2 (en) 2003-02-28 2004-09-10 Exonhit Therapeutics Sa Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis
WO2014202827A1 (en) 2013-06-11 2014-12-24 Orion Corporation Novel cyp17 inhibitors/antiandrogens

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6176485A (ja) * 1984-09-20 1986-04-18 Ss Pharmaceut Co Ltd 新規なγ−ピラン誘導体
WO2003074450A2 (en) * 2002-02-28 2003-09-12 The University Of Tennessee Research Corporation Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy
US20140005181A1 (en) * 2012-06-21 2014-01-02 Sanford-Burnham Medical Research Institute Small molecule antagonists of the apelin receptor for the treatment of disease
AR110412A1 (es) * 2016-12-22 2019-03-27 Orion Corp Inhibidores de la cyp11a1

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076445A2 (en) 2003-02-28 2004-09-10 Exonhit Therapeutics Sa Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis
WO2014202827A1 (en) 2013-06-11 2014-12-24 Orion Corporation Novel cyp17 inhibitors/antiandrogens

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230019496A (ko) * 2016-12-22 2023-02-08 오리온 코포레이션 Cyp11a1 (시토크롬 p450 모노옥시게나제 11a1) 억제제로서 피란 유도체
KR102826021B1 (ko) * 2016-12-22 2025-06-30 오리온 코포레이션 Cyp11a1 (시토크롬 p450 모노옥시게나제 11a1) 억제제로서 피란 유도체

Also Published As

Publication number Publication date
AR110412A1 (es) 2019-03-27
BR112019012906A2 (pt) 2019-12-03
CN116162084A (zh) 2023-05-26
IL285729A (en) 2021-09-30
IL267484B (en) 2021-09-30
MA47102B1 (fr) 2021-09-30
MX388538B (es) 2025-03-20
ES2880151T3 (es) 2021-11-23
JP2020502229A (ja) 2020-01-23
MX2019007373A (es) 2019-09-18
US20190359601A1 (en) 2019-11-28
AU2021203497B2 (en) 2022-11-10
IL285729B (en) 2022-02-01
AU2017380282A1 (en) 2019-08-01
CN110139861A (zh) 2019-08-16
TWI796205B (zh) 2023-03-11
EA039309B1 (ru) 2022-01-12
TW201835072A (zh) 2018-10-01
US20210347765A1 (en) 2021-11-11
US12030871B2 (en) 2024-07-09
EP3558981A1 (en) 2019-10-30
MA55983A (fr) 2022-03-23
US20200299280A1 (en) 2020-09-24
KR20250097993A (ko) 2025-06-30
DK3558981T3 (da) 2021-07-26
US20240308989A1 (en) 2024-09-19
EA201991513A1 (ru) 2019-11-29
KR20230019496A (ko) 2023-02-08
CY1124461T1 (el) 2022-07-22
US11098032B2 (en) 2021-08-24
JP7286825B2 (ja) 2023-06-05
NZ755395A (en) 2025-10-31
KR20190095950A (ko) 2019-08-16
CN116162084B (zh) 2025-12-09
CO2019007321A2 (es) 2019-07-31
TWI762544B (zh) 2022-05-01
AU2021203497A1 (en) 2021-07-01
EP3868756A1 (en) 2021-08-25
TN2019000189A1 (en) 2020-10-05
PL3558981T3 (pl) 2021-12-06
EP3558981B1 (en) 2021-05-26
PH12019550111A1 (en) 2020-03-09
HUE056540T2 (hu) 2022-02-28
CL2019001728A1 (es) 2019-09-27
PE20191137A1 (es) 2019-09-02
PT3558981T (pt) 2021-07-06
JP7025432B2 (ja) 2022-02-24
HRP20211255T1 (hr) 2021-11-12
JP2022078068A (ja) 2022-05-24
SI3558981T1 (sl) 2021-09-30
UA124640C2 (uk) 2021-10-20
KR102826021B1 (ko) 2025-06-30
AU2017380282B2 (en) 2021-06-24
LT3558981T (lt) 2021-08-25
CA3047370A1 (en) 2018-06-28
IL267484A (en) 2019-08-29
RS62198B1 (sr) 2021-08-31
CN110139861B (zh) 2022-12-30
US10717726B2 (en) 2020-07-21
TW202229264A (zh) 2022-08-01
WO2018115591A1 (en) 2018-06-28

Similar Documents

Publication Publication Date Title
KR102491308B1 (ko) Cyp11a1 (시토크롬 p450 모노옥시게나제 11a1) 억제제로서 피란 유도체
KR20230010723A (ko) Cyp11a1 억제제
US20240279210A1 (en) Inhibitors of rna helicase dhx9 and uses thereof
CN101370806A (zh) 取代的4-苯基哌啶
CN103402995A (zh) 新型吲哚、吲唑衍生物或其盐
JP6762300B2 (ja) アミノピラゾール誘導体
BR122024021737A2 (pt) Compostos derivados de pirano como inibidores de cyp11a1, uso dos mesmos para o tratamento de doenças dependentes de receptor esteroide, particularmente, receptor androgênico e composição e combinação farmacêuticas que compreendem os ditos compostos
BR112019012906B1 (pt) Compostos derivados de pirano como inibidores de cyp11a1, uso dos mesmos para o tratamento de doenças dependentes de receptor esteroide, particularmente, receptor androgênico e composição e combinação farmacêuticas que compreendem os ditos compostos
HK40016600B (en) Pyran derivatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitors
HK40016600A (en) Pyran derivatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190719

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200626

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220427

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20221017

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230118

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230119

End annual number: 3

Start annual number: 1

PG1601 Publication of registration